rosiglitazone has been researched along with Ventricular Dysfunction, Left in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akkoc, H; Akkus, M; Kelle, I; Topal, AE; Yilmaz, S | 1 |
| Blaner, WS; Drosatos, K; Goldberg, IJ; Homma, S; Jiang, H; Khan, RS; Schulze, PC; Son, NH; Trent, CM | 1 |
| Acar, G; Akcay, A; Citirik, C; Dogan, E; Sayarlioglu, H; Sokmen, A; Sokmen, G; Tuncer, C; Ucar, MA | 1 |
| Dörffel, K; Haemmerle, G; Mayer, B; Schrammel, A; Wölkart, G; Zechner, R | 1 |
| Carabello, BA; De Freitas, G; Ishiyama, M; Nemoto, S; Razeghi, P; Taegtmeyer, H | 1 |
| Achtari Jeanneret, L; Barras-Moret, AC; Carron, P; Deriaz-Chessex, S; Donzé, J; Fournier, Y; Gachoud, D; Moix, PA; Monti, M; Rossier, A; Wilson, P | 1 |
6 other study(ies) available for rosiglitazone and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Metformin HCl has curative effect on rebuilding of ventricular diastolic functions in high-fat-diet fed rats.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Liver; Male; Metformin; Myocardium; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Rosiglitazone; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
Peroxisome proliferator-activated receptor-γ activation prevents sepsis-related cardiac dysfunction and mortality in mice.
Topics: Animals; Fatty Acids; Heart Diseases; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myocardium; PPAR gamma; Rosiglitazone; Sepsis; Thiazolidinediones; Ventricular Dysfunction, Left | 2013 |
Effects of rosiglitazone on cardiac function in CAPD patients: a tissue Doppler study.
Topics: Adult; Blood Flow Velocity; Cohort Studies; Echocardiography, Doppler, Pulsed; Female; Heart Function Tests; Humans; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Probability; Prognosis; Prospective Studies; Reference Values; Risk Assessment; Rosiglitazone; Survival Analysis; Thiazolidinediones; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right | 2009 |
Cardiac dysfunction in adipose triglyceride lipase deficiency: treatment with a PPARα agonist.
Topics: Animals; Anticholesteremic Agents; Body Weight; Female; Heart; Heart Rate; In Vitro Techniques; Lipase; Male; Mice; Mice, Knockout; Myocardium; Norepinephrine; Organ Size; PPAR alpha; PPAR gamma; Pyrimidines; Rosiglitazone; Thiazolidinediones; Ventricular Dysfunction, Left | 2012 |
PPAR-gamma agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation.
Topics: Animals; Chronic Disease; Dogs; Hemodynamics; Male; Mitral Valve Insufficiency; Myocardial Contraction; Myocytes, Cardiac; PPAR gamma; Rosiglitazone; Thiazolidinediones; Triglycerides; Ventricular Dysfunction, Left | 2005 |
[Highlights 2007 in hospital-based internal medicine: the point of view from the chief residents].
Topics: Accidental Falls; Aged; Albuterol; Anemia; Anticoagulants; Antidiuretic Hormone Receptor Antagonists; Atrial Fibrillation; Attitude of Health Personnel; Benzazepines; Bronchitis, Chronic; Bronchodilator Agents; Cardiac Pacing, Artificial; Diabetes Mellitus; Endocarditis, Bacterial; Erythropoietin; Heart Failure; Heparin; Humans; Internal Medicine; Interprofessional Relations; Medical Staff, Hospital; Myocardial Infarction; Recombinant Proteins; Risk Management; Rosiglitazone; Salmeterol Xinafoate; Thiazolidinediones; Thromboembolism; Tolvaptan; Vasodilator Agents; Ventricular Dysfunction, Left; Workload | 2008 |